Tomoaki Sonoda

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

A Case of Enteric-Type Thymic Adenocarcinoma Treated with Lenvatinib.

A Case of Enteric-Type Thymic Adenocarcinoma Treated with Lenvatinib.

Journal: Internal medicine (Tokyo, Japan)

Published: May 17, 2026

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Journal: Translational lung cancer research

Published: February 20, 2026

Efficacy of Jiinshihoto on Depressive Symptoms in Patients With Pulmonary Mycobacterium avium-intracellulare Complex Disease not Receiving Standard Treatment.

Efficacy of Jiinshihoto on Depressive Symptoms in Patients With Pulmonary Mycobacterium avium-intracellulare Complex Disease not Receiving Standard Treatment.

Journal: Global advances in integrative medicine and health

Published: December 08, 2025

Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature.

Bullous Pemphigoid in Patients with Non-small-cell Lung Cancer Complicated by Diabetes Mellitus Receiving Dipeptidyl Peptidase-4 Inhibitors and Immune Checkpoint Inhibitors: A Case Report of Two Patients and Review of Literature.

Journal: Internal medicine (Tokyo, Japan)

Published: April 06, 2025

3'-deoxy-3'-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.

3'-deoxy-3'-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.

Journal: EJNMMI research

Published: October 28, 2024

Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer.

Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: September 02, 2024

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 19, 2024

A Case of Refractory Pemphigus Herpetiformis with Positive Anti-Desmoglein 1 Antibody: Case Report and Literature Review to Revisit the Disease Characteristics of 167 Cases.

A Case of Refractory Pemphigus Herpetiformis with Positive Anti-Desmoglein 1 Antibody: Case Report and Literature Review to Revisit the Disease Characteristics of 167 Cases.

Journal: Indian journal of dermatology

Published: August 09, 2024

Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.

Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.

Journal: Oncology

Published: November 08, 2023

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: April 28, 2023

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

Journal: Cancer chemotherapy and pharmacology

Published: March 08, 2023

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Journal: Cancer medicine

Published: January 31, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026